Superworth

IDEXX Laboratories EV/EBIT IDXX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2011.

Today, Nov 3, 2026
36.3×
10-year median
40.7×
Against its 10-year history
26th
percentile: 0 is its lowest day, 100 its highest
10-year range
27.3× to 74.6×
Peer median
30.8×

IDEXX Laboratories' EV/EBIT is 36.3× as of Nov 3, 2026.

That is below its ten-year median of 40.7×, lower than on 74% of days in the last ten years.

Over that time it ranged from 27.3× in Sep 2026 to 74.6× in Jul 2021.

The median for 10 diagnostics and research stocks of a similar size is 30.8×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far36.3×27.3×44.0×
202542.3×28.5×46.3×
202430.8×30.6×44.5×
202343.2×31.6×50.0×
202239.2×29.8×51.3×
202161.2×54.6×74.6×
202069.1×29.3×69.1×
201942.6×35.8×49.6×
201835.5×35.3×51.7×
201736.1×33.5×42.6×
201633.2×21.6×34.0×
201526.9×24.9×29.7×
201426.1×21.0×26.4×
201321.1×17.1×21.7×
201219.8×18.8×23.1×
201118.5×16.7×22.2×

Against its peers

Companies in Medical - Diagnostics & Research nearest IDEXX Laboratories' size, closest first, today.

CompanyEV/EBIT
IDXXIDEXX Laboratories36.3×
AAgilent Technologies30.9×
WATWaters128×
IQVIQVIA25.4×
ILMNIllumina36.6×
MTDMettler-Toledo International30.6×
LHLabcorp22.9×
DGXQuest Diagnostics19.0×
MEDPMedpace30.4×
DHRDanaher34.2×
RVTYRevvity44.2×
Peer median30.8×

Where IDEXX Laboratories ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on IDEXX Laboratories

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.